secwatch / observer
8-K filed December 28, 2023, 6:59 PM ET ticker BFRI CIK 0001858685
debt confidence high sentiment negative materiality 0.70

Biofrontera Inc. (BFRI): debt financing — Biofrontera enters $4M secured loan agreements maturing July 2024

Biofrontera Inc.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Biofrontera Inc. incurred term loan of $2,000,000 with Lender A maturing July 5, 2024.

Instrument
term loan
Principal
$2,000,000
Counterparty
Lender A
Maturity
July 5, 2024
Event
incurrence
Exact text from the filing
On December 21, 2023, Biofrontera, Inc. (the "Company") entered into (a) a Business Loan and Security Agreement (the "Agreement A") pursuant to which the lender ("Lender A") has made a term loan to the Company in the principal amount of $2,000,000 ("Loan A"), evidenced by a Secured Promissory Note, effective as of December 21, 2023 ("Note A"), made by the Company in favor of Lender A
View on SEC.gov
Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Biofrontera Inc. incurred term loan of $2,000,000 with Lender B maturing July 5, 2024.

Instrument
term loan
Principal
$2,000,000
Counterparty
Lender B
Maturity
July 5, 2024
Event
incurrence
Exact text from the filing
and (b) a Business Loan and Security Agreement ("Agreement B" and together with the Agreement A, the "Loan Agreements") pursuant to which the lender ("Lender B") has made a term loan to the Company in the principal amount of $2,000,000 (the "Loan B" and together with the Loan A, the "Loans"), evidenced by a Secured Promissory Note, effective as of December 21, 2023 ("Note B"), made by the Company in favor of Lender B.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Biofrontera Inc. entered into Business Loan and Security Agreements A and B with Lender A and Lender B valued at Two term loans of $2,000,000 each, total $4,000,000 (effective 2023-12-21).

Action
entry
Agreement
credit facility
Counterparty
Lender A and Lender B
Value
Two term loans of $2,000,000 each, total $4,000,000
Effective
2023-12-21
Exact text from the filing
On December 21, 2023, Biofrontera, Inc. (the “Company”) entered into (a) a Business Loan and Security Agreement (the “Agreement A”) pursuant to which the lender (“Lender A”) has made a term loan to the Company in the principal amount of $2,000,000 (“Loan A”), evidenced by a Secured Promissory Note, effective as of December 21, 2023 (“Note A”), made by the Company in favor of Lender A; and (b) a Business Loan and Security Agreement (“Agreement B” and together with the Agreement A, the “Loan Agreements”) pursuant to which the lender (“Lender B”) has made a term loan to the Company in the principal amount of $2,000,000 (the “Loan B” and together with the Loan A, the “Loans”), evidenced by a Secured Promissory Note, effective as of December 21, 2023 (“Note B”), made by the Company in favor of Lender B.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Biofrontera Inc. terminated Revolving line of credit with MidCap Business Credit LLC with MidCap Business Credit LLC valued at Voluntary termination of revolving line of credit that provided for maximum borrowings of $6.5 milli.

Action
termination
Agreement
credit facility
Counterparty
MidCap Business Credit LLC
Value
Voluntary termination of revolving line of credit that provided for maximum borrowings of $6.5 milli
Exact text from the filing
In connection with entering into the Agreement A and Agreement B, the Company is in the process of voluntarily terminating the revolving line of credit between the Company and MidCap Business Credit LLC that provided for maximum borrowings of $6.5 million, subject to a borrowing base and an availability block.
View on SEC.gov

Browse all debt financings →

Biofrontera Inc. filing history →

Source: SEC EDGAR
accession 0001493152-23-046414
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.